Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer
14 April 2020 - 6:30AM
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage
biopharmaceutical company focused on developing immunotherapies
based on gene-edited allogeneic CAR T-cells (UCART), today
announced the appointment of Carrie Brownstein, M.D., to the role
of Chief Medical Officer. In Dr. Brownstein’s new role, she will
oversee clinical research and development for Cellectis’ UCART
clinical trial programs. Dr. Brownstein joins Cellectis from
Celgene, with a strong track record in hematology and myeloid
diseases. She is assuming her new position based in the Cellectis
New York office and is joining the Company’s executive committee.
“We are thrilled to have Dr. Brownstein bringing
her strong industry expertise and impressive leadership at a time
when our three proprietary product candidates are advancing in
clinical studies,” said Dr. André Choulika, Chairman and CEO,
Cellectis. “Carrie has an impressive track record in clinical
development across all phases of the product lifecycle, including
successful regulatory filings in the US and EU for novel products.
With that solid experience, her hands-on approach and passion for
developing innovative therapies, I am confident that Carrie will be
a pivotal addition to our leadership team and I look forward to
working alongside her and the team to bring Cellectis’ allogeneic
CAR-T product candidates to patients in need.”
Dr. Brownstein joins Cellectis as a seasoned
clinical and medical expert from Celgene, where she most recently
served as Vice President, Global Clinical Research and Development,
Therapeutic Area Head for myeloid diseases. In this role, Dr.
Brownstein managed a clinical team of physicians and scientists
across multiple global sites and was responsible for management and
cross-functional development of products to treat patients with
myeloid diseases. Prior to Celgene, Dr. Brownstein served as
Executive Director, Clinical Sciences Oncology at Regeneron
Pharmaceuticals where she led teams investigating multiple early
development programs and assets, including T-cell engaging
bispecific antibodies. Dr. Brownstein started her industry career
at Hoffman-La Roche (Roche Pharmaceuticals), where she held roles
of increasing responsibility, and most recently served as Senior
Medical Director supporting the development and approval of a
number of hematology and oncology therapies. Prior to her career in
an industry setting, Dr. Brownstein practiced medicine as a
pediatric oncologist within notable New York institutions such as
New York Presbyterian Columbia University and Mount Sinai Medical
Center.
Dr. Brownstein received her M.D. from Tufts
University School of Medicine and completed her internship and
residency at the Babies and Children’s Hospital of Columbia
Presbyterian Medical Center (NYP, Morgan Stanley Children’s
Hospital) in New York, NY. She completed a fellowship in pediatric
hematology and oncology at Memorial Sloan Kettering Cancer Center
also New York, NY.
“Throughout my career, I’ve always been
passionate about the field of hematology and oncology and have
sought opportunities where I could make a meaningful impact on the
lives of patients with unmet medical needs,” noted Dr. Brownstein.
“Cellectis is a pioneer in gene editing and immuno-oncology and is
laying the groundwork to innovate the CAR T-cell field with their
allogeneic approach. I am eager to join Cellectis at such a pivotal
time, and look forward to joining the talented team and leading
these truly transformative therapies through the clinic towards
commercialization.”
About CellectisCellectis is
developing the first of its kind allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients. As a clinical-stage biopharmaceutical company with
over 20 years of expertise in gene editing, Cellectis is developing
life-changing product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation system
to harness the power of the immune system in order to target and
eradicate cancer cells.
As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing life-saving UCART
product candidates to address unmet needs for multiple cancers
including acute myeloid leukemia (AML), B-cell acute lymphoblastic
leukemia (B-ALL) and multiple myeloma (MM).
Cellectis headquarters are in Paris, France,
with additional locations in New York, New York and Raleigh, North
Carolina. Cellectis is listed on the Nasdaq Global Market (ticker:
CLLS) and on Euronext Growth (ticker: ALCLS). For more information,
visit www.cellectis.com.
Follow Cellectis on social media: @cellectis,
LinkedIn and YouTube.
TALEN® is a registered trademark owned by
Cellectis.
For further information, please
contact:
Media contacts:Jennifer Moore,
VP of Communications, 917-580-1088, media@cellectis.comCaitlin
Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com
IR contact:Simon Harnest, VP of
Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com
DisclaimerThis press release
contains “forward-looking” statements that are based on our
management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Further information on the risk factors
that may affect company business and financial performance is
included in Cellectis’ Annual Report on Form 20-F and the financial
report (including the management report) for the year ended
December 31, 2019 and subsequent filings Cellectis makes with the
Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
PDF available:
http://ml.globenewswire.com/Resource/Download/8218cb8a-317b-4217-9ac0-23eff2ef755c
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jul 2023 to Jul 2024